α5β1 inhibitor Therapy(Morphic Therapeutic)

N/A

Report date: 2024/09/13 10:06:37

Base Information

Drug Nameα5β1 inhibitor Therapy(Morphic Therapeutic)
Drug Alias NameIntegrin alpha-5 beta-1-inhibitors (Eli Lilly and Company)α5β1 inhibitors (Eli Lilly and Company)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-5/beta-1 inhibitors
TargetsIntegrin alpha-5/beta-1
Therapy Area/IndicationsPulmonary Arterial Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMorphic Therapeutic Inc
China Registration ClassN/A

Develop Information

Active CompaniesMorphic Therapeutic Inc
Inactive CompaniesN/A
Active IndicationsPulmonary Arterial Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A